




In another aspect, there is provided a process to manufacture a compound of formula I



comprising the step of reacting a compound of formula (II)



5 with a compound of formula (III)



wherein n, m, R², R³, X¹⁻⁴ and Y¹⁻⁴ are as defined hereinabove for formula (I).

In another aspect, there is provided a compound of formula I as defined herein for use as therapeutically active substance.

10 In another aspect, there is provided a compound of formula I as defined herein for the use as therapeutically active substance acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

In another aspect, there is provided a pharmaceutical composition comprising a compound of formula I as defined herein and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.

- 5 In another aspect, there is provided use of a compound of formula I as defined herein for the manufacture of a medicament for acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

6-methyl-1'-(4'-oxo-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-2'-yl)-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidin]-1-one.

11. A compound of formula I as defined in any of claims 1 to 10, selected from the group consisting of

5 2'-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one,

1'-(4'-oxo-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-2'-yl)-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one,


10 2'-(6-methyl-1H,1'H-spiro[furo[3,4-c]pyridine-3,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one,

2'-(3-methyl-1'H,5H-spiro[furo[3,4-b]pyridine-7,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one, and


2'-(3-methyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one.

15 12. A compound of formula I as defined in any of claims 1 to 11 that is 2'-(7,7-dimethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one.


13. A process to manufacture a compound of formula I



20 comprising the step of reacting a compound of formula (II)



with a compound of formula (III)



wherein n, m, R², R³, X¹⁻⁴ and Y¹⁻⁴ are as defined in any of claims 1 to 12 for formula (I).

14. A compound of formula I according to any of claims 1 to 12 for use as therapeutically active substance.
- 5 15. A compound of formula I according to claims 1 to 12 for the use as therapeutically active substance acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
- 10 16. A pharmaceutical composition comprising a compound of formula I according to any of claims 1 to 12 and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.
- 15 17. Use of a compound of formula I according to any of claims 1 to 12 for the manufacture of a medicament for acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
